Interim report 1 January - 30 September 2009
- Net sales amounted to SEK 151.2 million (106.0), an increase of SEK
45.2 million (43%).
- Operating profit was SEK 36.4 million (18.4), an increase of SEK 18
million.
- Profit before tax was SEK 42.6 million (20.1), an increase of SEK
22.5 million.
- Due to the earlier cumulative loss carry forward, BioGaia pays no
tax. Profit after reported tax was SEK 29.3 million (31.1), a
decrease of SEK 1.8 million. The period's reported tax expense of SEK
13.3 million refers to a change in the deferred tax asset. Profit for
the corresponding period of last year included a deferred tax benefit
of SEK 11.0 million.
- Earnings per share after reported tax amounted to SEK 1.70 (1.81).
- The period's cash flow from operating activities before change in
working capital was SEK 40.0 million (23.3). Total cash flow for the
period was SEK 29.7 million (15.7). Cash and cash equivalents at 30
September 2009 amounted to SEK 87.5 million.
Third quarter 1 July - 30 September 2009
- Net sales for the third quarter amounted to SEK 38.7 million
(33.6), an increase of SEK 5.1 million (15%) over the same period of
last year. Including early deliveries from the second quarter, sales
rose by 31%.
- Operating profit was SEK 6.4 million (5.8), an increase of SEK 0.6
million.
- Profit before tax was SEK 11.3 million (6.5), an increase of SEK
4.8 million.
- Due to the earlier cumulative loss carry forward, BioGaia pays no
tax. Profit after reported tax was SEK 7.7 million (9.0), a decrease
of SEK 1.3 million. The period's reported tax expense of SEK 3.6
million refers to a change in the deferred tax asset. Profit for the
corresponding period of last year included a deferred tax benefit of
SEK 2.5 million.
Key events in the third quarter of 2009
- Agreement with Laboratoires BIOETHIC for the sale of BioGaia's
Probiotic tablets and drops in France.
Key events after the end of the reporting period
- Agreement with Pharma Nord for the sale of BioGaia's Probiotic
tablets and drops in Denmark.
".we are continuing to see very satisfactory growth with sustained
gross margins and a strong cash flow. In the first three quarters of
the year our sales rose by 43%, a trend that reflects the rising
demand we are noting in various markets and the pace of our product
launches. It is also satisfying that the BioGaia brand accounted for
a full 32% of our sales of finished consumer products, which is the
result of a deliberate focus on developing our own brand." says
Managing Director Peter Rothschild.
For additional information contact:
Peter Rothschild, Managing Director, telephone +46 8 - 555 293 00
Jan Annwall, Deputy Managing Director, telephone +46 8 - 555 293 00
(Figures in brackets refer to the same period of last year)
